Celyad Oncology SA

Equities

CYAD

BE0974260896

Biotechnology & Medical Research

Market Closed - Euronext Bruxelles Other stock markets 11:55:00 2026-01-15 am EST			5-day change	1st Jan Change
0.1730 ^EUR	-1.14%		-8.71%	+1.76%

25-09-30	Celyad Oncology to Sell Belgian Research Facility for EUR3 Million	MT
25-09-29	Celyad Oncology announces research facility divestiture	RE

Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2024

Published on 04/02/2025 at 01:00 pm EDT

S&P Capital IQ

Celyad Oncology SA

-1.14%

Celyad Oncology SA reported earnings results for the full year ended December 31, 2024. For the full year, the company reported sales was EUR 0.186 million compared to EUR 0.102 million a year ago. Net loss was EUR 5.82 million compared to EUR 8.45 million a year ago.

Basic loss per share from continuing operations was EUR 0.14.

Latest news about Celyad Oncology SA

25-09-30	Celyad Oncology to Sell Belgian Research Facility for EUR3 Million	MT
25-09-29	Celyad Oncology announces research facility divestiture	RE
25-09-28	An undisclosed buyer agreed to acquire Research facility?s equipment and office furniture in Mont-Saint-Guibert, Belgium of Celyad Oncology SA for ?3 million.	CI
25-09-25	Celyad Oncology SA Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-08-26	Celyad Oncology Announces Discontinuation of R&D Activities and Workforce	CI
25-07-28	Celyad Oncology to Receive EUR1 Million Capital Injection from Shareholder	MT
25-07-27	Celyad Oncology SA announced that it expects to receive ?1 million in funding from CFIP CLYD (UK) Limited	CI
25-06-25	Celyad Oncology Begins Strategic Review Amid Limited Financial Runway	MT
25-06-24	Celyad Oncology Announces Strategic Review	CI
25-04-02	Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-02-18	Celyad: share price soars on encouraging data
25-02-18	Celyad Oncology Announces the Publication of the Preclinical and Clinical Data of CYAD-211 Providing Proof-Of-Concept of Its miRNA-Based shRNA Platform	CI
24-09-17	Celyad Oncology Names New CEO to Start in October	MT
24-09-16	Celyad Oncology Appoints Matt Kane as Chief Executive Officer, Effective October 1, 2024	CI
24-09-13	Celyad Oncology SA Reports Earnings Results for the Half Year Ended June 30, 2024	CI
24-04-04	Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI
24-02-09	Celyad Oncology Seeks Termination of Reporting Obligations to US SEC	MT
23-12-05	Celyad Oncology CEO Resigns	MT
23-12-04	Celyad Oncology CEO Steps Down for Personal Reasons	MT
23-12-04	Celyad Oncology SA Announces Executive Change	CI
23-12-04	Celyad Oncology Sa Announces Executive Change	CI
23-11-13	Celyad Oncology SA announced that it has received ?9.794 million in funding from CFIP CLYD (UK) Limited, Fortress Investment Group LLC, Tolefi S.A.	CI
23-09-26	Celyad Oncology to Cancel American Depository Receipt Program in October	MT
23-09-05	Celyad Oncology SA, H1 2023 Earnings Call, Sep 05, 2023
23-09-04	Celyad Oncology SA Reports Earnings Results for the Half Year Ended June 30, 2023	CI

Chart Celyad Oncology SA

Duration

Period

CYAD: Dynamic Chart

Company Profile

Celyad Oncology SA is a biotechnology company focused on the discovery and development of innovative technologies chimeric antigen receptor (CAR) T-cell therapies. The company is focusing on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property and support the development of next-generation CAR T candidates in solid tumors and hematological malignancies.

Employees

Sector

Biotechnology & Medical Research

Calendar

Mar. 18 - Q4 2025 Earnings Release (Projected)

More about the company

Income Statement and Estimates

More financial data